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SUMMARY 
Background: Carbapenemase-producing Enterobacteriaceae (CPE) are an emerging infection 
control problem in hospitals worldwide. Identifying carriers may help reduce potential spread 
and infections. 
Aim: To assess whether testing hospital wastewater for CPE can supplement patient-based 
screening for infection prevention purposes in a hospital without a recognized endemic CPE 
problem. 
Methods: Wastewater collected from hospital pipework on 16 occasions during 
February‒March 2014 was screened for CPE using chromID® CARBA agar and chromID® 
CPS agar with a 10 µg ertapenem disc and combination disc testing. Minimum inhibitory 















methodology and carbapenemase genes detected by polymerase chain reaction or whole-
genome sequencing. Selected isolates were typed by pulsed-field gel electrophoresis.  
Findings: Suspected CPE were recovered from all 16 wastewater samples. Of 17 isolates sent 
to the Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, six 
(four Citrobacter freundii and two Enterobacter cloacae complex) were New Delhi metallo-
β-lactamase (NDM) producers and the remaining 11 (six Klebsiella oxytoca and five 
Enterobacter cloacae complex) were Guiana-Extended-Spectrum-5 (GES-5) producers, the 
first to be described among Enterobacteriaceae in the UK. The four NDM-producing C. 
freundii, two NDM-producing E. cloacae complex, and four out of five GES-5-producing E. 
cloacae complex were each indistinguishable isolates of the same three strains, whereas the 
six GES-5-producing K. oxytoca overall shared 79% similarity. 
Conclusion: CPE are readily isolated from hospital wastewater using simple culture methods. 
There are either undetected carriers of CPE excreting into the wastewater, or these CPE 
represent colonization of the pipework from other sources. Surveillance of hospital 








The emergence of carbapenemase-producing Enterobacteriaceae (CPE) is a concern 
for hospitals worldwide.1,2 Isolation of an organism that exhibits carbapenem resistance from 
an infected site may require the use of less effective antibiotics and poses an infection control 
risk to other patients. Patients who are asymptomatic faecal carriers of these organisms also 
pose an infection control risk.3 In most UK hospitals, CPE are only isolated sporadically, 
most often from patients who have recently received healthcare in countries where CPE have 
become endemic. However, a few UK hospitals, most notably in the north-west of England, 
have had endemic CPEs for several years, which have not been eradicated despite strenuous 
screening and isolation programmes.4 National guidance has been issued by Public Health 
England (PHE) to reduce the risk of further spread. This advice rejects screening all 
admissions for the presence of CPE as this would be costly and time-consuming, and 
recommends that ‘high-risk’ patients, including those with a history of foreign travel and 















Confirmation that this selective approach is adequate in any single hospital would require a 
prolonged period of comprehensive screening, to capture any cases missed by risk factor-
based screening. Testing hospital wastewater for the presence of CPE offers a potential 
alternative approach, based on the assumption that carriers would excrete CPE into the 
hospital wastewater and that CPE would be present at a detectable level there with isolates not 
dissimilar to those from patients. Potentially this method could provide hospital infection 
control teams with assurance that a latent endemic CPE problem is not present if testing were 
negative, and do so at much lower cost than universal screening of all admissions.  
In this study, samples of wastewater collected over a two-month period from a single 
UK hospital, without a known endemic CPE problem, were screened for CPE in order to 
determine whether there was an unrecognized CPE presence within the hospital.  
Methods 
Study setting 
The study was conducted at Royal Preston Hospital, a 709-bed hospital in north-west 
England offering secondary care to an immediate population of ~140,000 and a range of 
tertiary care services to the population of Lancashire and South Lakeland, ~1.5 million.6 
There is substantial ethnic diversity within the catchment, with ~13% of the local population 
having family ties with the Indian subcontinent.6 Since May 2011 there has been a screening 
programme to detect carriage of CPE, with rectal swabs collected in all patients with a history 
of hospitalization overseas or within a healthcare facility in the UK with CPE problems. 
Patients who have had contact with a confirmed case, or who have previously been infected or 
colonized, are also screened. The programme was updated in line with PHE guidance issued 
in 2013.5 The hospital has comprehensive antibiotic guidance that imposes tight restrictions 
on the use of carbapenems and fluroquinolones, and limits cephalosporin use.  
Sample collection and processing 
Wastewater samples were collected twice a week during February and March 2014, 
producing a total of 16 samples. Sampling was facilitated by the introduction of a tap into the 
wastewater pipework in the basement directly beneath the wards. The wastewater sampled 
was from operating theatres, critical care unit, paediatrics, orthopaedics, cardiac ward, cardiac 
catheter laboratory, oncology, and a staff toilet block. The wastewater had not undergone any 
treatment prior to the sampling point. The first 100 mL was run off and discarded to reduce 
risk of cross-contamination between samples. Fifty microlitres of each sample were 
inoculated on to chromID® CARBA agar and chromID® CPS agar (both bioMérieux, 
Basingstoke, UK) plus a 10 µg ertapenem disc (Mast Group Ltd, Bootle, UK). Cultures were 















Isolate identification  
Blue, green, or pink colonies growing within ≤27 mm of the ertapenem disc on the 
chromID CPS agar or on the chromID CARBA agar were presumed to be CPE isolates. All 
presumptive CPE colonies from both media were further analysed. Oxidase-negative, Gram-
negative isolates were subcultured from both media on to cysteine lactose electrolyte-deficient 
(CLED) agar (E&O Laboratories Ltd, Bonnybridge, UK) and incubated at 35‒37°C for 
18‒24 h. Bacterial identification was determined by matrix-assisted laser 
desorption‒ionization mass spectrometry (MALDI-TOF MS; Bruker Daltonik GmbH, 
Bremen, Germany) as previously described.7 Isolates from the Enterobacteriaceae family 
were further characterized to determine carbapenemase production.  
Antibiotic susceptibility determination 
Isolates were tested for resistance to meropenem and ertapenem using the British 
Society for Antimicrobial Chemotherapy (BSAC) disc diffusion method and zone sizes 
interpreted using BSAC guidelines.8 Isolates were also screened for synergy between 
meropenem and dipicolinic acid [for presumptive identification of metallo-β-lactamases 
(MBLs)], phenylboronic acid [Klebsiella pneumoniae carbapenemase (KPC)] and 
phenylboronic acid and cloxacillin (AmpC) using the KPC/MBL and OXA-48 confirmation 
kit (Bioconnections, Knypersley, UK). The first 13 isolates recovered in the study were 
referred to Public Health England’s Antimicrobial Resistance and Healthcare Associated 
Infections (AMRHAI) Reference Unit as they showed resistance to ertapenem and 
meropenem with unclear but presumptive carbapenemase production using the methods 
described above. Additional carbapenem-resistant organisms were recovered as the study 
continued; however, only those that were presumptively identified as MBL producers were 
referred (due to limited resources) to AMRHAI in order to confirm the resistance mechanism. 
Therefore, 17 isolates were referred and minimum inhibitory concentrations (MICs) were 
determined by BSAC agar dilution using AMRHAI’s standard Gram-negative antibiotic 
panel, including ertapenem, meropenem and imipenem (the latter tested with/without 
320 mg/L EDTA to detect likely MBL producers). MICs were interpreted using BSAC 
breakpoints where available. Isolates were also screened for carbapenemase activity using the 
Rosco Rapid Carb test (Bioconnections) and the modified Hodge test. 
Molecular detection of carbapenemases 
In-house polymerase chain reaction (PCR) was used to screen for class A (KPC and 
IMI), class B (NDM, IMP, VIM, GIM, SIM, SPM), and class D (OXA-48-like) 
carbapenemase genes.9‒13 Whole-genome sequencing (WGS) of three isolates with 















Chesterford, UK) and data were analysed using an in-house bioinformatics pipeline. 
Resistance genes were identified in WGS data by mapping reads against a library of known 
resistance genes curated in-house and assembled from publicly accessible databases.14 
Typing 
The 17 isolates submitted to the reference laboratory were typed by pulsed-field gel 
electrophoresis of XbaI-digested genomic DNA. Gel images were analysed and compared 
using Bionumerics software, version 6.1 (Applied Maths, Sint-Martins-Latem, Belgium).  
Results 
Suspected CPE isolates were recovered from all 16 wastewater samples. The 55 
colonies recovered (35 from chromID CARBA agar and 20 from chromID CPS agar + 
ertapenem disc) included 21 Klebsiella oxytoca, 21 Enterobacter cloacae complex, nine 
Citrobacter freundii, three Citrobacter braakii, and one Citrobacter youngae. BSAC disc 
diffusion determined that all 55 were intermediate or resistant to meropenem or ertapenem. 
Combination disc testing identified 16 presumptive KPC producers, six presumptive MBL 
producers, and seven isolates gave indeterminate results. Carbapenemase activity was not 
detected in the 26 isolates as determined by the interpretation of the combination discs. In 
total, 17 suspected CPE (as described earlier) were sent to AMRHAI for further 
characterization.  
Minimum inhibitory concentrations are shown in Table I. All isolates were resistant to 
the three carbapenems tested (ertapenem MICs ≥8 mg/L; meropenem and imipenem MICs 
≥32 mg/L). At least eight-fold synergy between imipenem and EDTA was noted for six 
isolates (four C. freundii and two E. cloacae complex), all of which had been identified as 
presumptive MBL-producing isolates by the KPC/MBL and OXA-48 confirmation kit, and 
blaNDM genes were detected by PCR in these isolates. Typing of these isolates showed that 
both the two E. cloacae complex and four C. freundii isolates were each genetically 
indistinguishable within each group (data not shown). 
The remaining six K. oxytoca isolates (four presumptively identified as KPC-
producers and two as AmpC producers) and five E. cloacae complex isolates (three 
presumptively identified as KPC producers, and two in which no carbapenemase activity was 
detected) were highly carbapenem-resistant (ertapenem MICs ≥8 mg/L, meropenem; 
imipenem MICs ≥32 mg/L) with no significant imipenem/EDTA synergy (Table I). However, 
these 11 isolates were negative using in-house carbapenemase PCRs, and no carbapenemase 
activity was detected using the Rosco Rapid Carb test or modified Hodge test. Whole-genome 
sequencing of three of these isolates identified the non-metallo-carbapenemase blaGES-5, 















isolates. Typing of the six K. oxytoca isolates showed that they had similar but not identical 
profiles, sharing 79% genetic similarity. Four of the five E. cloacae isolates were 
representatives of a single strain, whereas the fifth had a distinct pattern (Table I). 
Discussion 
Carbapenem-resistant organisms were readily detected in the wastewater of the 
hospital. This was unexpected as only a small number of confirmed CPE had been detected 
between 2010 and 2014 from screening (430 screens) and clinical isolates within the hospital 
(six KPC, one NDM, and four OXA-48-like CPE since 2010; AMRHAI, unpublished data). 
The absence of KPC-producing organisms in the wastewater was also surprising given their 
relatively high incidence in north-west England.15 KPC-producing Enterobacteriaceae form 
the majority of the carbapenemase-producing organisms referred to PHE, with ~75% of KPC 
producers coming from clinical or screening specimens taken from hospitals in north-west 
England.5,16,17  
 Local circumstances may affect the presence of CPE in the wastewater. Overuse of 
carbapenems may promote the recovery of CPE. Consumption of carbapenem antibiotics in 
2013 within this hospital was 10.9 defined daily doses (DDD) per 100 admissions per day 
compared with 8.0 DDD per 100 admissions per day for England.18 Most carbapenem 
prescriptions require infection specialist approval, with only a few indications (e.g. post-
neurosurgical meningitis) bypassing this stricture. In 2011, 13.7% of the local population had 
connections with the Indian subcontinent and therefore may have travelled frequently to areas 
with endemic CPE and become colonized. However, only 5% of admissions with recorded 
ethnicity data are within this group.6  
 This study has several limitations. The sampling window covered only two months. 
However, consistent recovery of CPE from all samples suggests that this is an ongoing 
problem, and, from a sample collected in March 2015, carbapenem-resistant organisms of the 
same species were isolated. The method used to collect and test the wastewater is not formally 
recognized, as this involves filtration. The aim, however, was to produce a simple and 
inexpensive method, so that any hospital’s infection prevention team could realistically 
request monitoring of the wastewater for the presence of CPE. The small sample volume may 
reduce CPE but each sample recovered carbapenem-resistant organisms, indicating not only 
success but also potential underestimation. A further limitation is that only 17 out of 55 
isolates were sent to AMRHAI for confirmatory testing. The remaining 38 isolates yielded 
varied results (extended-spectrum β-lactamase, KPC, AmpC, or undetermined) using the 
ROSCO discs, similar to those seen in 11 GES-5 positive isolates referred. We cannot 















their consistent detection in earlier samples, and the similar range of species and resistance 
profiles found.   
 There have been several studies indicating that chromID CARBA agar is highly 
sensitive for the detection of CPE. Perry et al. determined 100% sensitivity and 93% 
specificity for a prototype of the CARBA agar; however, this was only for detection of NDM-
1 carbapenemase producers whereas Vrioni et al. showed 92.4% sensitivity and 96.9% 
specificity for a prototype CARBA agar.19,20 A more recent study in Greece determined a 
sensitivity of 96.5% and specificity of 91.2% (before Gram staining) and 100% (after Gram 
staining) for the final chromID CARBA product, indicating that this is a good choice for a 
screening method.21 Unfortunately the chromID CARBA plate has been reported to not 
reliably detect OXA-48-like producers, which may correlate with the zero recovery in this 
study.22 Whereas OXA-48-like carbapenemases are becoming more widespread in the UK, 
until 2012 they were identified less frequently than KPC, NDM, and VIM carbapenemases.23 
Agar plates allowing more sensitive detection of OXA-48-like carbapenemases are now 
available and may need to be considered in future studies.24,25 
 A total of 55 isolates were recovered across 16 samples over a two-month time period. 
It is possible that isolates were counted twice after being detected on both media. A biofilm 
may have built up in the tap with the repeat isolates recovered from here rather than a 
continuing presence in the wastewater itself. To minimize this, a 100 mL run-off was 
performed and discarded before sampling. In future studies a tap-cleaning brush could be used 
to reduce any physical build-up. However, the aim of this study was to determine whether 
carbapenem-resistant organisms could be identified using this method and whether CPE were 
present (rather than how many were present), which it has succeeded in doing. The protocol 
allows scope for further investigation using more quantitative methods to determine the extent 
of the presence of carbapenem-resistant organisms within our hospital.  
The presence of GES-5-producing Enterobacteriaceae in the wastewater did not 
equate, in this hospital, with a clinical problem. Similarly, although NDM producers were 
recovered from the hospital wastewater, the only patient isolate with an NDM carbapenemase 
detected at the hospital’s laboratory had been a K. pneumoniae isolated from a community 
urine specimen in 2010. We therefore found no link between isolates causing colonization or 
infection of inpatients and those present in wastewater. However, since screening is limited to 
those patients with risk factors, in accordance with current PHE guidance, the possibility that 
unidentified carriers within the hospital may be a reservoir for GES-5 and NDM-1 















The typing results indicated that the same strains were recovered on several occasions 
over the two-month time period: the six NDM-positive isolates of C. freundii and the two E. 
cloacae complex isolates represented just two strains. In addition, four out of five E. cloacae 
GES-5-producing isolates were indistinguishable. This suggests that these particular strains 
may be persisting in the wastewater environment rather than having been excreted repeatedly 
by patients, and may not be of clinical significance. Prior to this study, GES-5-positive 
Enterobacteriaceae had not been described in the UK. Enterobacteriaceae producing the GES-
5 carbapenemase have been isolated from clinical specimens in Korea and Southern 
Brazil.26,27 Wastewater is a potential habitat for the horizontal transfer of resistance genes, and 
the presumptive presence of excreted antimicrobials from patients into the wastewater allows 
for the selection of resistant bacteria.28 Hospital wastewater is not routinely tested for CPE, so 
the prevalence of GES-5 or other carbapenemases in bacteria from this source is unknown. 
Manageiro et al. found GES-5-producing K. pneumoniae in water streams in Portugal, 
highlighting aquatic environments as a potential reservoir for resistance mechanisms.29  
This study also highlights the uncertainty as to whether GES-5-producing isolates can 
be reliably confirmed using the phenotypic methods used to confirm suspected CPE. As noted 
in this and previous studies, GES carbapenemases may not be reliably detected by 
colorimetric tests such as the Rosco Rapid Carb and some CarbaNP tests, and selected 
isolates from this study were negative in the modified Hodge test.30 The identification of GES 
carbapenemase activity is not covered specifically by combination disc tests, although seven 
out of 11 were flagged as KPC producers, so would be further investigated. KPC and GES-5 
are class A carbapenemases and thus both are inhibited by phenylboronic acid. All isolates 
were, however, highly resistant to carbapenems and thus would warrant sending to a reference 
laboratory, even if local testing failed to show carbapenemase production. Although there is 
potential for underdetection of GES-5, AMRHAI has had no previous isolates of 
Enterobacteriaceae from UK laboratories with gross carbapenem resistance in the absence of 
one of the more widespread carbapenemase genes (KPC, OXA, NDM, VIM, IMP).  
 In conclusion, a simple culture method was able to isolate CPE from hospital 
wastewater. However, there appears to be little correlation between the carbapenemases found 
and the hospital’s experience of CPE-positive samples from patients. This suggests that the 
isolates may be adapted to the environment and consistently present within the pipework. 
Whereas comprehensive screening of both patients and staff would be needed to accurately 
describe the correlation between human isolates and presence of CPE in wastewater, the 
possible presence of CPEs of environmental origin severely limits the role of this approach 
















We are grateful to the Microbiology Laboratory and the Facilities Department for 
installation of the tap, with special thanks to P. Hickey and S. Hughes. 
Conflict of interest statement 
J.C., P.W., K.L.H., R.P., D.M., C.P., R.P. and N.W. have no personal conflicts to declare. 
However, PHE’s AMRHAI Reference Unit has received financial support for conference 
attendance, lectures, research projects or contracted evaluations from numerous sources, 
including: Achaogen Inc, Allecra Antiinfectives GmbH, Amplex, AstraZeneca UK Ltd, 
Becton Dickinson Diagnostics, bioMérieux, Bio-Rad Laboratories, the British Society for 
Antimicrobial Chemotherapy (BSAC), Cepheid, Check-Points BV, Cubist 
Pharmaceuticals, Department of Health, Enigma Diagnostics Ltd., Eumedica, Food 
Standards Agency, Glaxo Smithkline Services Ltd, Henry Stewart Talks, IHMA Ltd, 
Merck Sharpe & Dohme Corp, Meiji Seika Kiasya Ltd, Momentum Biosciences Ltd, 
Nordic Pharma Ltd, Norgine Pharmaceuticals, Rempex Pharmaceuticals Ltd, Rokitan Ltd, 
Smith & Nephew UK Ltd, Tetraphase Pharmaceuticals, Trius Therapeutics, VenatoRx, 
Wockhardt Ltd. 
Funding sources 
Funding was provided through L.J.W.’s training post. L.J.W. received conference support 
from Healthcare Infection Society to attend and present this research as an oral 
presentation at FIS 2014. 
References 
1. Wei WJ, Yang HF, Ye Y, et al. New Delhi metallo-β-lactamase-mediated carbapenem 
resistance: origin, diagnosis, treatment and public health concern. Chin Med J (Engl) 
2015;128:1969‒1976. 
2. Jain A, Hopkins KL, Turton J, et al. NDM carbapenemases in the United Kingdom: an 
analysis of the first 250 cases. J Antimicrob Chemother 2014;69:1777‒1784. 
3. Zhao ZC, Xu XH, Liu MB, et al. Fecal carriage of carbapenem-resistant 
Enterobacteriaceae in a Chinese university hospital. Am J Infect Control 
2014;42:e61‒e64. 
4. Central Manchester University Hospitals NHS Foundation Trust. Infection, prevention 
and control annual report 2013/2014. Available at: 
https://www.cmft.nhs.uk/media/892227/agenda%20item%2084%20annual%20infection
%20control%20report.pdf [last accessed July 2015]. 
5. Public Health England. Acute trust toolkit for the early detection, management and 
















ute_trust_toolkit_for_the_early_detection.pdf [last accessed September 2015]. 
6. Office for National Statistics. NOMIS Official labour market statistics. Available at: 
http://www.nomisweb.co.uk/ [last accessed February 2016]. 
7. Cherkaoui A, Hibbs J, Emonet S, et al. Comparison of two matrix-assisted laser 
desorption ionization-time of flight mass spectrometry methods with conventional 
phenotypic identification for routine identification of bacteria to the species level. J Clin 
Microbiol 2010;48:1169‒1175. 
8. British Society of Antimicrobial Chemotherapy (BSAC) Working Party on Susceptibility 
Testing. BSAC methods of antimicrobial susceptibility testing. Version 14, January 2015. 
Available at: http://bsac.org.uk/wp-content/uploads/2012/02/BSAC-disc-susceptibility-
testing-method-Jan-2015.pdf [last accessed November 2015]. 
9. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-
lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. 
Antimicrob Agents Chemother 2001;45:1151‒1161. 
10. Rasmussen BA, Bush K, Keeney D, et al. Characterization of IMI-1 beta-lactamase, a 
class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae. Antimicrob Agents 
Chemother 1996;40:2080‒2086. 
11. Mushtaq S, Irfan S, Sarma JB, et al. Phylogenetic diversity of Escherichia coli strains 
producing NDM-type carbapenemases. J Antimicrob Chemother 2011;66:2002‒2005. 
12. Ellington MJ, Kistler J, Livermore DM, et al. Multiplex PCR for rapid detection of genes 
encoding acquired metallo-beta-lactamases. J Antimicrob Chemother 2007;59:321‒322. 
13. Poirel L, Héritier C, Tolün V, et al. Emergence of oxacillinase-mediated resistance to 
imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004;48:15‒22. 
14. Doumith M, Day M, Ciesielczuk H, et al. Rapid identification of major Escherichia coli 
sequence types causing urinary tract and bloodstream infections. J Clin Microbiol 
2015;53:160‒166. 
15. Cantón R, Akóva M, Carmeli Y, et al. Rapid evolution and spread of carbapenemases 
among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012;18:413‒431. 
16. Davies SC. Annual report of the Chief Medical Officer, volume two, 2001, infections and 
the rise of antimicrobial resistance. London: Department of Health; 2013. Available at: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/138331/C
 MO_Annual_Report_Volume_2_2011.pdf [last accessed April 2015]. 
17. Health Protection Unit. Healthcare-associated infection and antimicrobial resistance: 
















/HPAwebFile/HPAweb_C/1317136146912 [last accessed April 2015]. 
18. Public Health England. English Surveillance Programme for antimicrobial utilisation 
and resistance. PHE; 2014. Available at: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/362374/ES
PAUR_Report_2014__3_.pdf [last accessed February 2016]. 
19. Perry JD, Naqvi SH, Mirza IA, et al. Prevalence of faecal carriage of Enterobacteriaceae 
with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two 
chromogenic media. J Antimicrob Chemother 2011;66:2288‒2294. 
20. Vrioni G, Daniil I, Voulgari E, et al. Comparative evaluation of a prototype chromogenic 
medium (ChromID CARBA) for detecting carbapenemase-producing Enterobacteriaceae 
in surveillance rectal swabs. J Clin Microbiol 2012;50:1841‒1846. 
21. Papadimitriou-Olivgeris M, Bartzavali C, Christofidou M, et al. Performance of chromID 
CARBA medium for carbapenemases-producing Enterobacteriaceae detection during 
rectal screening. Eur J Clin Microbiol Infect Dis 2014;33:35‒40. 
22. Wilkinson KM, Winstanley TG, Lanyon C, et al. Comparison of four chromogenic 
culture media for carbapenemase-producing Enterobacteriaceae. J Clin Microbiol 
2012;50:3102‒3104. 
23. Public Health England. Carbapenemase-producing Enterobacteriaceae: laboratory 
confirmed cases, 2003 to 2013. Available at: 
https://www.gov.uk/government/publications/carbapenemase-producing-
enterobacteriaceae-laboratory-confirmed-cases/carbapenemase-producing-
enterobacteriaceae-laboratory-confirmed-cases-2003-to-2013 [last accessed September 
2015]. 
24. Girlich D, Anglade C, Zambardi G, et al. Comparative evaluation of a novel 
chromogenic medium (chromID OXA-48) for detection of OXA-48 producing 
Enterobacteriaceae. Diagn Microbiol Infect Dis 2013;77:296‒300. 
25. Girlich D, Poirel L, Nordmann P. Comparison of the SUPERCARBA, CHROMagar 
KPC, and Brilliance CRE screening media for detection of Enterobacteriaceae with 
reduced susceptibility to carbapenems. Diagn Microbiol Infect Dis 2013;75:214‒217. 
26. Ribeiro VB, Falci DR, Rozales FP, et al. Carbapenem-resistant GES-5-producing 
Klebsiella pneumoniae in Southern Brazil. Braz J Infect Dis 2014;18:231‒232. 
27. Jeong SH, Bae IK, Kim D, et al. First outbreak of Klebsiella pneumoniae clinical isolates 
producing GES-5 and SHV-12 extended-spectrum beta-lactamases in Korea. Antimicrob 















28. Ottosson JR, Jarnheimer PA, Stenstrom TA, et al. A longitudinal study of antimicrobial 
resistant faecal bacteria in sediments collected from a hospital wastewater system. Infect 
Ecol Epidemiol 2012;2 [Epub 2012 Mar 27]. 
29. Manageiro V, Ferreira E, Caniça M, et al. GES-5 among the β-lactamases detected in 
ubiquitous bacteria isolated from aquatic environment samples. FEMS Microbiol Lett 
2014;351:64‒69. 
30. Tijet N, Boyd D, Patel SN, et al. Evaluation of the Carba NP test for rapid detection of 
carbapenemase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob 


















Susceptibility patterns and genes identified for the 17 isolates referred to the Antimicrobial Resistance and Healthcare Associated Infections 
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ATM 8 8 8 16 8 16 0.5 0.25 4 8 8 8 >64 ≤0.1
25 
1 0.25 0.25 
CTX-CLOX 16 0.5 32 64 1 32 256 1 0.25 32 32 32 64 256 128 256 256 
CTX 64 4 64 >256 32 128 256 2 4 128 128 64 64 256 128 256 256 
CTX-CLA 2 8 2 >32 >32 16 >32 2 16 2 2 2 8 >32 >32 >32 >32 
CAZ 16 16 16 >256 64 32 >256 4 8 16 16 16 256 >256 >256 >256 >256 
CAZ-CLA 8 8 16 >32 8 8 >32 2 16 16 8 8 8 >32 >32 >32 >32 
FEP 16 0.25 32 32 1 16 64 0.5 0.25 32 32 16 16 64 64 >64 64 
FEP-CLA 1 0.25 2 >32 1 0.5 >32 0.5 0.25 1 1 1 1 >32 >32 >32 >32 
IPM-EDTA >16 16 >16 2 >16 >16 1 >16 >16 >16 >16 >16 >16 1 2 1 1 















MEM >32 32 >32 32 >32 32 32 >32 32 >32 >32 >32 >32 >32 >32 >32 >32 
ETP >16 8 >16 >16 >16 >16 >16 >16 >16 >16 >16 >16 >16 >16 >16 >16 >16 
COL ≤0.5 2 ≤0.5 >32 >32 16 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 >32 1 1 
AMK 4 2 4 1 4 4 2 4 4 8 8 4 2 2 2 2 2 
GEN >32 >32 >32 1 >32 >32 >32 >32 >32 >32 >32 >32 >32 >32 0.5 >32 >32 
KOX, Klebsiella oxytoca; ECLO, Enterobacter cloacae complex; CFR, Citrobacter freundii; NDM, New Delhi metallo-β-lactamase; PFGE, 
pulsed-field gel electrophoresis; ATM, aztreonam; CTX-CLOX, cefotaxime/cloxacillin (100 mg/L); CTX, cefotaxime; CTX-CLA, 
cefotaxime/clavulanate (4 mg/L); CAZ, ceftazidime; CAZ-CLA, ceftazidime/clavulanate; FEP, cefepime; FEP-CLA, cefepime/clavulanate; IPM-
EDTA, imipenem/EDTA (320 mg/L); IPM, imipenem; MEM, meropenem; ETP, ertapenem; COL, colistin; AMK, amikacin; GEN, gentamicin.  
P1KL-1, P1KL-1′ and P1KL-1′′, shared 79% genetic similarity. 
 
